Across TCGA pan-cancer cohorts, TRAV12-1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TRAV12-1 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TRAV12-1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAV12-1 expression acts as an unfavorable survival marker.
KIRC are the cancer types where TRAV12-1 Mutation most reproducibly stratifies survival.